Why the study?
Spironolactone is recommended for resistant hypertension, warranting a review of its pharmacodynamic and pharmacokinetic profile and role in therapy.
This narrative review summarizes the pharmacodynamic and pharmacokinetic profile of spironolactone and its established role in treating resistant hypertension.
Affirms spironolactone's established role in resistant hypertension; leaves open optimization in subgroups pending new trials.
Spironolactone is a competitive nonselective mineralocorticoid receptor blocker with high affinity for aldosterone; therefore, it is widely used as a diuretic and antihypertensive. Because of these properties it is used in the treatment of edema in congestive heart failure, liver cirrhosis with ascites and edema, nephrotic syndrome, malignant ascites, severe heart failure and primary hyperaldosteronism. Spironolactone is recommended for the treatment of resistant hypertension. Narrative review aims to present the pharmacodynamic and pharmacokinetic profile of spironolactone, and describe its position in the treatment of resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Dragojević-Simić et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: